Most Recent Articles by Deborah Weinstein
NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.
Analysts say head-to-head study results could make Kyprolis the lead treatment.
Potential patients are expected to be newly diagnosed diabetes patients as opposed to Lantus switchers.
Millennials and baby boomers have a lot of common: a desire for technology that supports health priorities.
Smartphones drove network traffic.
More Articles by Deborah Weinstein
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- Poll shows all ages seek digital health tools
- Survey shows docs overestimate adherence
- Drugmaker shifts sales model to keep pace with formulary decision making
- Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence
- Global cancer drug market to grow to $111 billion by 2020: report